Additionally, the mutation confers resistance to Braf inhibition by vemurafenib and dabrafenib in vitro, suggesting a role of Rac1P29S mutation as a biomarker for Raf inhibitor resistance in melanoma patients (12). This evidence concerns the gene BRAF and melanoma.